CLDI

Calidi Biotherapeutics Inc

May 15 • 04:00PM ET

0.1856

-0.0043 -2.26 %

Healthcare • Biotechnology • USA • Nano • AMEX

May 14, 4:51 PMCalidi Biotherapeutics reports Q1 2026 non-GAAP EPS -$2.21 (-2% YoY) on zero revenue, misses EPS estimates

Peers: PSTV LIXT IMNN BCTX BCDA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.18	Insider Own	10.23%	Shs Outstand	11.79M	Perf Week	-11.83%
Market Cap	3.58M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.08%	Shs Float	9.78M	Perf Month	-33.04%
Enterprise Value	-0.89M	PEG	-	EPS next Q	-	Inst Own	6.31%	Short Float	31.07%	Perf Quarter	-76.28%
Income	-25.01M	P/S	-	EPS this Y	-	Inst Trans	2.63%	Short Ratio	0.79	Perf Half Y	-87.71%
Sales	0.00M	P/B	0.44	EPS next Y	-	ROA	-202.88%	Short Interest	3.04M	Perf YTD	-84.14%
Book/sh	0.42	P/C	0.53	EPS next 5Y	-	ROE	-421.19%	52W High	19.20 -99.03%	Perf Year	-96.27%
Cash/sh	0.35	P/FCF	-	EPS past 3/5Y	74.50% -	ROIC	-439.70%	52W Low	0.18 4.56%	Perf 3Y	-99.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.02% 11.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	76.55%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.92	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	32.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.92	EPS Q/Q	80.60%	SMA20	-13.73%	Beta	1.34	Target Price	120.00
Payout	-	Debt/Eq	0.46	Sales Q/Q	-	SMA50	-28.10%	Rel Volume	0.89	Prev Close	0.19
Employees	29	LT Debt/Eq	0.15	Earnings	May 14 AMC	SMA200	-86.42%	Avg Volume	3.87M	Price	0.19
IPO	Nov 01, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	3,459,697	Change	-2.26%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-23	Initiated	H.C. Wainwright	Buy	$11
Oct-09-23	Initiated	Robert W. Baird	Outperform	$9

May-14-26 04:10PM	Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights (GlobeNewswire) -5.05%
May-13-26 08:00AM	Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston (GlobeNewswire) +8.11%
Apr-29-26 08:00AM	Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI (GlobeNewswire) -6.88%
Apr-21-26 08:00AM	Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 (GlobeNewswire) -11.35%
Apr-20-26 08:00AM	Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 (GlobeNewswire) -9.02%
08:00AM	Loading…
Apr-15-26 08:00AM	Calidi Biotherapeutics Announces Participation in RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms (GlobeNewswire)
Apr-14-26 08:00AM	Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavik, Iceland on April 28th Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy (GlobeNewswire)
Apr-07-26 08:00AM	Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy (GlobeNewswire)
Apr-02-26 08:00AM	Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 (GlobeNewswire)
Apr-01-26 08:00AM	Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 (GlobeNewswire)
Mar-27-26 04:25PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -11.67%
Mar-24-26 08:00AM	Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials (GlobeNewswire)
Mar-12-26 08:00AM	Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing (GlobeNewswire)
Mar-09-26 08:50PM	Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
Mar-06-26 08:30AM	Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering (GlobeNewswire) -53.14%
02:15AM	Loading…
02:15AM	Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours - Here's Why (Benzinga)
Mar-05-26 05:57PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire)
Feb-20-26 08:00AM	Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference (GlobeNewswire) +7.97%
Feb-12-26 08:00AM	Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference (GlobeNewswire) -6.89%
Jan-28-26 08:00AM	Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 (GlobeNewswire)
Nov-17-25 08:00AM	Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 (GlobeNewswire)
Nov-13-25 04:15PM	Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire)
Nov-10-25 08:00AM	Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC (GlobeNewswire)
Nov-04-25 08:00AM	Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting (GlobeNewswire)
Oct-30-25 08:00AM	Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting (GlobeNewswire) +6.04%
Oct-22-25 08:00AM	Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine (GlobeNewswire) -5.26%
Sep-29-25 08:00AM	Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston (GlobeNewswire)
Sep-02-25 08:00AM	Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-21-25 06:33PM	Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
Aug-20-25 09:15AM	Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering (GlobeNewswire) -42.67%
04:15PM	Loading…
Aug-08-25 04:15PM	Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -13.02%
Aug-01-25 11:23AM	Titan of Industry Allan Camaisa Teams Up with Res Nova Bio to Advance Breast Cancer Immunotherapy (PR Newswire)
Jul-29-25 08:00AM	Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma (GlobeNewswire) +14.94%
Jul-25-25 04:45PM	Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 (GlobeNewswire) -5.43% -24.71%
Jul-22-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 (GlobeNewswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) +42.57%
08:30AM	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment (GlobeNewswire)
Jul-09-25 02:01PM	Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds (GlobeNewswire) +108.96%
Jul-08-25 08:30AM	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment (GlobeNewswire) +39.47%
Jun-27-25 08:00AM	Calidi Biotherapeutics Announces Shareholder Letter from CEO (GlobeNewswire)
Jun-02-25 08:00AM	Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting (GlobeNewswire)
May-16-25 09:55AM	Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-14-25 04:30PM	Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -8.47%
Apr-28-25 08:00AM	Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting (GlobeNewswire)
Apr-25-25 08:00AM	Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
Apr-23-25 08:00AM	Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director (GlobeNewswire)
Apr-22-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 (GlobeNewswire) +6.59%
Apr-17-25 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors (GlobeNewswire)
Apr-10-25 08:00AM	Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor (GlobeNewswire)
Mar-31-25 04:30PM	Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -12.89%
04:10PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Mar-28-25 09:00AM	Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -6.53%
Mar-26-25 08:00AM	Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma (GlobeNewswire)
Mar-14-25 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +9.25%
Mar-11-25 02:00PM	IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform (NewMediaWire)
Mar-10-25 08:00AM	Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform (GlobeNewswire) -7.07%
Feb-28-25 09:00AM	Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +5.56%
Feb-24-25 08:00AM	Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital (GlobeNewswire) -7.52%
Jan-29-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 (GlobeNewswire)
Jan-28-25 08:00AM	Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement (GlobeNewswire)
Jan-13-25 08:00AM	Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025 (GlobeNewswire)
Jan-10-25 04:30PM	Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock (GlobeNewswire) -32.22%
08:30AM	Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock (GlobeNewswire)
Jan-08-25 04:01PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire) -8.16%
Nov-18-24 08:00AM	Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer (GlobeNewswire) +7.31%
Nov-15-24 04:05PM	Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock (GlobeNewswire) +8.96%
Nov-14-24 08:30AM	Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock (GlobeNewswire) -40.53%
Nov-13-24 04:33PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire) +60.19%
Nov-12-24 05:29PM	Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +26.35%
Oct-25-24 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +29.76%
Oct-24-24 08:35AM	Calidi to sell 2.05M shares at $1.00 in registered direct offering (TipRanks)
08:30AM	Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences (GlobeNewswire)
Oct-23-24 08:31AM	Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -26.54%
Oct-19-24 05:48PM	Calidi Biotherapeutics Faces Warrant Delisting by NYSE (TipRanks)
Oct-18-24 11:00PM	NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) (GlobeNewswire) -7.38%
08:45AM	Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Sep-30-24 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma (GlobeNewswire) -5.79%
Aug-13-24 05:37PM	Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.71%
Aug-02-24 09:00AM	GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.38%
Jul-29-24 09:00AM	Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor (GlobeNewswire)
Jul-18-24 08:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform (GlobeNewswire) -8.43%
Jul-16-24 08:00AM	Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board (GlobeNewswire) +7.42%
Jul-05-24 04:15PM	Calidi to Effect Reverse Stock Split (Business Wire) -18.30%
Jun-27-24 07:00AM	Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors (Business Wire)
Jun-11-24 04:05PM	Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13 (Business Wire) +31.71% -16.67%
Jun-10-24 07:00AM	Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidis Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors (Business Wire) +6.22%
Jun-03-24 07:00AM	Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting (Business Wire) +15.79%
May-31-24 08:51AM	Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds (Business Wire) -36.67%
May-24-24 09:00AM	ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
May-17-24 09:00AM	Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV (ACCESSWIRE) -5.99%
May-14-24 04:05PM	Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results (Business Wire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +7.95%
May-01-24 07:00AM	Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (Business Wire)
Apr-23-24 07:00AM	Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24 (Business Wire) +7.05%
Apr-19-24 04:05PM	Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering (Business Wire)
Apr-16-24 08:31AM	Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering (Business Wire) -65.48%
Apr-09-24 07:00AM	Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Companys Novel Immunotherapies at the AACR Annual Meeting 2024 (Business Wire) +62.39%
Mar-15-24 04:05PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results (Business Wire) -5.81%
Mar-11-24 07:00AM	Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer (Business Wire)
Feb-12-24 07:00AM	Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference (Business Wire)

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

CEO & DirectorDr. Eric E. Poma Ph.D.

CFO & Corporate SecretaryMr. Andrew C. Jackson

Pharm.D.Dr. Antonio Fernandez Santidrian Ph.D.

Chief Medical OfficerDr. Guy Travis Clifton M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Camaisa Allan	Director	Dec 12 '25	Sale	1.46	850	1,237	76,952	Dec 16 07:37 PM
Schoeneck James A	Director	Aug 21 '25	Buy	2.00	75,000	150,000	76,134	Aug 25 08:47 PM
Poma Eric E	Chief Executive Officer	Aug 21 '25	Buy	2.00	25,000	50,000	25,000	Aug 25 08:47 PM
Leftwich Scott	Director	Aug 21 '25	Buy	2.00	125,000	250,000	130,650	Aug 25 08:47 PM
Jackson Andrew C.	Chief Financial Officer	Aug 21 '25	Buy	2.00	2,500	5,000	2,500	Aug 25 08:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDI

Calidi Biotherapeutics Inc

Upgrade your Finviz experience